利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.016 秒)

    PYRROLIDINE SUBSTITUTE FLAVONES FOR THE TREATMENT OF INFLAMMATORY DISORDERS
    2.
    发明申请
    PYRROLIDINE SUBSTITUTE FLAVONES FOR THE TREATMENT OF INFLAMMATORY DISORDERS 有权
    用于治疗炎症性疾病的吡咯啉替代性FLAVONES

    公开(公告)号：US20120316216A1

    公开(公告)日：2012-12-13

    申请号：US13580815

    申请日：2010-02-26

    申请人： Kalpana Sanjay Joshi ,  Sapna Hasit Parikh

    发明人： Kalpana Sanjay Joshi ,  Sapna Hasit Parikh

    IPC分类号： A61K31/4025 ,  A61P19/02 ,  A61P19/10 ,  A61P9/00 ,  A61P17/00 ,  A61P1/04 ,  A61P17/06 ,  A61P1/00 ,  A61P11/00 ,  A61P29/00 ,  A61P9/10

    CPC分类号： C07D405/04 ,  A61K31/4025 ,  C07D409/04

    摘要： The present invention relates to the use of a compound of formula 1, a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof, for the treatment of an inflammatory disorder. The invention further relates to a pharmaceutical composition comprising a compound of formula 1 and at least one pharmaceutically acceptable carrier, for use in the treatment of an inflammatory disorder. The invention also relates to a method for the treatment of an inflammatory disorder by administering a therapeutically effective amount of the compound of formula 1 to a subject in need thereof.

    摘要翻译： 本发明涉及式1化合物，其立体异构体或其互变异构体或其药学上可接受的盐或其药学上可接受的溶剂化物在治疗炎症性疾病中的用途。 本发明还涉及包含式1化合物和至少一种药学上可接受的载体的药物组合物，其用于治疗炎症性疾病。 本发明还涉及通过向有需要的受试者施用治疗有效量的式1化合物来治疗炎症性疾病的方法。

    ANTICANCER USE OF CAFFEIC ACID AND ITS DERIVATIVES
    3.
    发明申请
    ANTICANCER USE OF CAFFEIC ACID AND ITS DERIVATIVES 审中-公开
    安非他酮及其衍生物的使用方法

    公开(公告)号：US20100010002A1

    公开(公告)日：2010-01-14

    申请号：US12439587

    申请日：2007-08-20

    申请人： Kalpana Sanjay Joshi ,  Meenakshi Sivakumar ,  Valmik Sopan Aware ,  Vilas Sampatrao Wagh ,  Amit Deshpande ,  Ankush Gangaram Sarde ,  Somesh Sharma

    发明人： Kalpana Sanjay Joshi ,  Meenakshi Sivakumar ,  Valmik Sopan Aware ,  Vilas Sampatrao Wagh ,  Amit Deshpande ,  Ankush Gangaram Sarde ,  Somesh Sharma

    IPC分类号： A61K31/192 ,  A61K31/495 ,  A61P35/00

    CPC分类号： A61K31/192 ,  A61K31/165 ,  A61K31/216 ,  A61K31/445 ,  A61K31/4453 ,  A61K31/495 ,  A61K31/506 ,  A61K31/5375 ,  A61K45/06 ,  A61K2300/00

    摘要： The present invention relates to the use of caffeic acid or a derivative thereof represented by the following general formula (1) wherein X is O, NH, or heterocyclyl; R may be present or absent and if present, is H, alkyl, aryl, or heterocyclyl; in all its stereoisomeric and tautomeric forms, and mixtures thereof in all ratios, and a pharmaceutically acceptable salt, pharmaceutically acceptable solvate, pharmaceutically acceptable polymorph or a prodrug, in the treatment of chronic myeloid leukemia (CML) which is resistant to treatment with GLEEVEC. The invention also relates to a method for reducing the proliferation of cells that are resistant to GLEEVEC by contacting the cells with a compound of general formula (1). The present invention also relates to pharmaceutical compositions (for the manufacture of the medicament) including caffeic acid or a derivative or a salt thereof represented by the general formula (1) for the treatment of chronic myeloid leukemia (CML) that is resistant to treatment with GLEEVEC, or for reducing the proliferation of cells that are resistant to GLEEVEC. The present invention further relates to a method of treatment of chronic myeloid leukemia (CML) that is resistant to treatment with GLEEVEC.

    摘要翻译： 本发明涉及由以下通式（1）表示的咖啡酸或其衍生物的用途，其中X为O，NH或杂环基; R可以存在或不存在，如果存在，是H，烷基，芳基或杂环基; 所有其立体异构体和互变异构体形式及其混合物，以及药学上可接受的盐，药学上可接受的溶剂合物，药学上可接受的多晶型物或前药，用于治疗耐受GLEEVEC治疗的慢性骨髓性白血病（CML）。 本发明还涉及通过使细胞与通式（1）的化合物接触来降低对GLEEVEC有抗性的细胞增殖的方法。 本发明还涉及包含通式（1）表示的咖啡酸或其衍生物或其盐的药物组合物（用于制备药物），其用于治疗耐药治疗的慢性骨髓性白血病（CML） GLEEVEC，或用于减少对GLEEVEC耐药细胞的增殖。 本发明还涉及对GLEEVEC治疗有抗性的慢性骨髓性白血病（CML）的治疗方法。

    Pyrrolidine-substituted flavones as radio-sensitizers for use in the treatment of cancer
    4.
    发明授权
    Pyrrolidine-substituted flavones as radio-sensitizers for use in the treatment of cancer 有权
    吡咯烷取代的黄酮作为用于治疗癌症的放射敏感剂

    公开(公告)号：US08895605B2

    公开(公告)日：2014-11-25

    申请号：US13318235

    申请日：2010-05-03

    申请人： Maggie Joyce Rathos ,  Kalpana Sanjay Joshi ,  Nikhil Krishnamurthy Hebbar ,  Somesh Sharma

    发明人： Maggie Joyce Rathos ,  Kalpana Sanjay Joshi ,  Nikhil Krishnamurthy Hebbar ,  Somesh Sharma

    IPC分类号： A61K31/4025 ,  C07D311/32 ,  A61P35/00 ,  A61K31/00

    CPC分类号： A61K31/00 ,  A61K31/4025 ,  A61K2300/00

    摘要： The present invention relates to a combination for the treatment of cancer wherein the combination exhibits a synergistic effect. The combination comprises radiation and at least one cyclin dependent kinase (CDK) inhibitor selected from the compounds of formula I or a pharmaceutically acceptable salt or a solvate thereof. The present invention also relates to a method for the treatment of cancer, which method comprises administering to a patient in need of such a treatment, a therapeutically effective amount of the combination. The present invention also relates to the use of a CDK inhibitor selected from the compounds of formula I as a radiosensitizer that enhances the efficacy of radiotherapy for the treatment of cancer, particularly head and neck cancer.

    摘要翻译： 本发明涉及用于治疗癌症的组合，其中组合表现出协同效应。 该组合包括辐射和至少一种选自式I化合物的细胞周期蛋白依赖性激酶（CDK）抑制剂或其药学上可接受的盐或溶剂合物。 本发明还涉及一种治疗癌症的方法，该方法包括向需要这种治疗的患者施用治疗有效量的组合。 本发明还涉及选自式I化合物的CDK抑制剂作为放射增敏剂的用途，其增强了放射治疗癌症尤其是头颈癌的疗效。

    Styrenyl 1,2,4-oxadiazole compounds
    5.
    发明授权
    Styrenyl 1,2,4-oxadiazole compounds 失效
    苯乙烯基-1,2,4-恶二唑化合物

    公开(公告)号：US08629277B2

    公开(公告)日：2014-01-14

    申请号：US13580928

    申请日：2011-02-24

    申请人： Meenakshi Sivakumar ,  Kalpana Sanjay Joshi ,  Valmik Sopan Aware ,  Ankush Gangaram Sarde ,  Sandeep Maruti Bagul ,  Sonal Mohan Manohar

    发明人： Meenakshi Sivakumar ,  Kalpana Sanjay Joshi ,  Valmik Sopan Aware ,  Ankush Gangaram Sarde ,  Sandeep Maruti Bagul ,  Sonal Mohan Manohar

    IPC分类号： C07D413/06 ,  C07D271/06

    CPC分类号： C07D271/06 ,  C07D413/06

    摘要： The present invention relates to oxadiazole compounds in all their stereoisomeric and tautomeric forms and mixtures thereof in all ratios; and their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutically acceptable prodrugs and pharmaceutically acceptable polymorphs. The invention also relates to processes for the manufacture of the oxadiazole compounds and to pharmaceutical compositions containing them. The said compounds and their pharmaceutical compositions are useful in the treatment of cancer, particularly chronic myeloid leukemia (CML). The present invention further provides a method of treatment of cancer by administering a therapeutically effective amount of said compounds or their pharmaceutical compositions, to a mammal in need thereof.

    摘要翻译： 本发明涉及所有其立体异构互变异构形式的恶二唑化合物及其混合物; 及其药学上可接受的盐，药学上可接受的溶剂化物，药学上可接受的前药和药学上可接受的多晶型物。 本发明还涉及制备恶二唑化合物的方法和含有它们的药物组合物。 所述化合物及其药物组合物可用于治疗癌症，特别是慢性骨髓性白血病（CML）。 本发明还提供了一种通过向有需要的哺乳动物施用治疗有效量的所述化合物或其药物组合物来治疗癌症的方法。

    Pyrrolidine substitute flavones for the treatment of inflammatory disorders
    6.
    发明授权
    Pyrrolidine substitute flavones for the treatment of inflammatory disorders 有权
    吡咯烷替代黄酮治疗炎症性疾病

    公开(公告)号：US08906953B2

    公开(公告)日：2014-12-09

    申请号：US13580815

    申请日：2010-02-26

    申请人： Kalpana Sanjay Joshi ,  Sapna Hasit Parikh

    发明人： Kalpana Sanjay Joshi ,  Sapna Hasit Parikh

    IPC分类号： A61K31/353 ,  A61K31/4025 ,  A61P19/02 ,  C07D311/32 ,  C07D405/04 ,  C07D409/04

    CPC分类号： C07D405/04 ,  A61K31/4025 ,  C07D409/04

    摘要： The present invention relates to the use of a compound of formula 1, a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof, for the treatment of an inflammatory disorder. The invention further relates to a pharmaceutical composition comprising a compound of formula 1 and at least one pharmaceutically acceptable carrier, for use in the treatment of an inflammatory disorder. The invention also relates to a method for the treatment of an inflammatory disorder by administering a therapeutically effective amount of the compound of formula 1 to a subject in need thereof.

    摘要翻译： 本发明涉及式1化合物，其立体异构体或其互变异构体或其药学上可接受的盐或其药学上可接受的溶剂化物在治疗炎症性疾病中的用途。 本发明还涉及包含式1化合物和至少一种药学上可接受的载体的药物组合物，其用于治疗炎症性疾病。 本发明还涉及通过向有需要的受试者施用治疗有效量的式1化合物来治疗炎症性疾病的方法。

    HERBAL COMPOSITION AND PROCESS FOR ITS PREPARATION
    8.
    发明申请
    HERBAL COMPOSITION AND PROCESS FOR ITS PREPARATION 失效
    草本组合物及其制备方法

    公开(公告)号：US20100028472A1

    公开(公告)日：2010-02-04

    申请号：US12520198

    申请日：2007-02-20

    申请人： Kalpana Sanjay Joshi ,  Vilas Wagh ,  Somesh Sharma

    发明人： Kalpana Sanjay Joshi ,  Vilas Wagh ,  Somesh Sharma

    IPC分类号： A61K36/00 ,  A61P35/02

    CPC分类号： A61K36/67 ,  A61K9/009 ,  A61K9/1617 ,  A61K9/1623

    摘要： A herbal composition comprising a therapeutically effective amount of the extract of Piper betle leaves as an active ingredient either alone, or with a pharmaceutically acceptable excipient. A process for the preparation of the herbal composition is provided. The herbal composition is adapted for the treatment of chronic myeloid leukemia (CML; chronic myelogenous leukemia) showing resistance to treatment with imatinib (Gleevec® or Glivec®).

    摘要翻译： 一种草药组合物，其包含治疗有效量的Pi叶提取物作为单独的活性成分或与药学上可接受的赋形剂。 提供了一种制备草药组合物的方法。 草药组合物适用于治疗显示对用伊马替尼治疗（Gleevec或Glivec）的抗性的慢性骨髓性白血病（CML;慢性骨髓性白血病）。